Warner Chilcott PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Warner Chilcott PLC
Apellis Follows Wave Life By Shelving ALS Candidate After Trial Miss
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
Ginkgo Bioworks, Boehringer Enter Into Drug Discovery Partnership
Deal Snapshot: Ginkgo will earn up to $406m in fees plus royalties as it works with Boehringer Ingelheim to mine its metagenomics database for drug candidates.
Avidity’s Phase I/II Success In Myotonic Dystrophy Obscured By Caveats
The US firm’s lead antibody oligonucleotide conjugate candidate has improved muscle strength and mobility in an early muscular dystrophy trial but some experts are disappointed by dose-specific data and a serious adverse event.
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
- Generic Drugs
- Topical Delivery
- Other Names / Subsidiaries
- Galen Holdings PLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.